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Abstract
Introduction:  Induced  sputum  with  hypertonic  saline  has  been  suggested  as  a  safer  and  cheaper
alternative to  bronchoalveolar  lavage  for  evaluation  of  patients  with  interstitial  lung  diseases
(ILD).
Objective:  To  evaluate  the  safety  and  feasibility  of  sputum  induction  in  ILD  and  to  compare
sputum cellular  proﬁles  with  paired  bronchoalveolar  lavage  ﬂuid  results.
Materials  and  methods:  Twenty  patients  underwent  sputum  induction  with  4.5%  saline  within
2 weeks  of  bronchoalveolar  lavage.  Total,  differential  cell  counts  and  cellular  viability  were
assessed.  Wilcoxon  test  and  Spearman’s  rank  correlation  coefﬁcient  were  used  and  a  p  <  0.05
was considered  statistically  signiﬁcant.
Results: From  a  total  of  20  subjects  (mean  age  49.4  ±  16.4  years,  70%  male)  a  satisfactory
sputum sample  was  obtained  in  15  subjects  (75%).  Induction  was  stopped  in  one  subject,  due  to
a signiﬁcant  decrease  in  PEF.  The  cell  proﬁles  for  induced  sputum  and  bronchoalveolar  lavage
ﬂuid (BALF)  were  different  (p  <  0.05),  except  for  eosinophils,  and  there  were  no  signiﬁcant
correlations  between  the  two  methods.  Compared  to  sputum  reference  values  there  was  an
increase of  lymphocytes  (3.2%  vs  0.5%)  and  eosinophils  (1.4%  vs  0.0%).  Comparing  sarcoidosis
and hypersensitivity  pneumonitis  sputum,  both  diseases  had  an  increase  in  lymphocytes  (4.4
vs 3.9%),  with  a  signiﬁcant  higher  neutrophil  count  in  hypersensitivity  pneumonitis  (65.4%  vs
10.6% p  <  0.05),  a  ﬁnding  also  seen  in  BALF.
Conclusion:  Induced  sputum  is  feasible  and  safe  in  interstitial  lung  diseases.  Although  sputum
cellular  counts  are  not  correlated  with  bronchoalveolar  lavage  ﬂuid,  sputum  cellular  proﬁles
may help  to  distinguish  different  ILD.
© 2012  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Esputo  induzido  nas  doenc¸as pulmonares  intersticiais  -  um  estudo  piloto
Resumo
Introduc¸ão:  A  induc¸ão  de  esputo  com  soro  hipertónico  tem  sido  apontada  como  uma  alterna-
tiva, mais  económica  e  segura,  ao  lavado  broncoalveolar  na  avaliac¸ão  de  doentes  com  doenc¸a
pulmonar  intersticial  (DPI).
Objetivo: Avaliar  a  seguranc¸a e  a  exequibilidade  do  esputo  induzido  nas  DPI  e  comparar  os
perﬁs celulares  do  estudo  com  os  resultados  obtidos  por  lavado  broncoalveolar.
Material  e  métodos: Vinte  doentes  realizaram  induc¸ão  de  esputo  com  soro  hipertónico  (4,5%)
num intervalo  de  2  semanas  após  a  realizac¸ão  de  lavado  broncoalveolar.  Foram  analisadas
as contagens  diferenciais  e  a  viabilidade  celular.  Para  a  análise  foram  utilizados  os  testes  de
Wilcoxon e  a  correlac¸ão  de  Spearman’s  e  um  valor  de  p  <  0,05  foi  considerado  estatisticamente
signiﬁcativo.
Resultados:  Dos  20  sujeitos  estudados  (média  de  idade  49,4  ±  16,4  anos,  70%  do  sexo  mas-
culino), foi  obtida  uma  amostra  satisfatória  de  esputo  em  15  (75%).  A  induc¸ão  foi  interrompida
num doente,  devido  a  uma  queda  signiﬁcativa  do  PEF.  Os  perﬁs  celulares  obtidos  do  esputo
induzido e  do  lavado  broncoalveolar  foram  distintos  (p  <  0,05),  com  excec¸ão  dos  eosinóﬁlos,  e
não se  veriﬁcaram  correlac¸ões  estatisticamente  signiﬁcativas  entre  os  2  métodos.  Comparando
os resultados  do  esputo  com  os  valores  de  referência,  veriﬁcou-se  um  aumento  de  linfócitos
(3,2 vs.  0,5%)  e  eosinóﬁlos  (1,4  vs.  0,0%).  Quando  se  compararam  os  resultados  do  esputo  dos
doentes  com  sarcoidose  e  pneumonite  de  hipersensibilidade,  ambos  os  grupos  apresentaram
um aumento  de  linfócitos  (4,4  vs.  3,9%)  e  a  contagem  de  neutróﬁlos  estava  signiﬁcativamente
aumentada  na  pneumonite  de  hipersensibilidade  (65,4  vs.  10,6%;  p  <  0,05),  achado  também
presente  no  lavado.
Conclusão:  O  esputo  induzido  é  um  método  seguro  e  exequível  nas  DPI.  Embora  as  contagens
celulares  obtidas  não  se  correlacionem  com  as  do  lavado,  os  perﬁs  celulares  do  esputo  podem
ajudar na  distinc¸ão  das  diferentes  DPI.
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nterstitial  lung  diseases  (ILDs),  also  known  as  diffuse
arenchymal  lung  diseases,  are  a  heterogeneous  group  of
ulmonary  disorders  with  different  etiopathogenesis,  treat-
ent  and  prognoses.  Although  some  reports  suggest  that  the
revalence  and  incidence  of  ILDs  has  increased  during  recent
ecades,  no  population-based  longitudinal  studies  have  doc-
mented  recent  trends  in  ILD  subgroups.1After  evaluation
f  symptoms,  pulmonary  function  tests  and  thoracic  imag-
ng,  direct  invasive  methods,  such  as  bronchoalveolar  lavage
BAL),  transbronchial  biopsy  and/or  surgical  lung  biopsy
re  usually  required  to  conﬁrm  the  diagnosis.2 BAL  is  the
tandard  procedure  recommended  in  the  European  Respi-
atory  Society  and  American  Thoracic  Society  statements
or  the  diagnostic  work-up  of  patients  with  ILD.2 BAL  is
seful  in  the  diagnosis  of  less  frequent  ILD  disorders  (e.g.
ccupational,  eosinophilic  lung  diseases,  Langerhans  cell
istyocitosis),  and  to  support  the  diagnosis  of  the  most
revalent  ILDs  (e.g.  sarcoidosis,  hypersensitivity  pneumoni-
is,  idiopathic  pulmonary  ﬁbrosis)  in  the  absence  of  a
ulmonary  biopsy.  In  fact,  depending  on  the  inﬂammatory
ell  pattern  revealed  in  BAL  and  according  to  the  patient
linical  history  and  radiological  ﬁndings,  the  biopsy  with
nherent  risks  may  be  obviated.3 Although  BAL  is  a  mini-
ally  invasive  technique,  with  minimal  risk  to  patients  when
dministered  properly,  patient  compliance  to  the  procedure
s  a  common  problem.  Additionally,  BAL  is  not  recommended
or  screening  programs,  nor  to  evaluate  exposures  and
ollow-up,  and  is  contraindicated  in  some  patients.3--6
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Induced  sputum  (IS)  by  inhalation  of  hypertonic  saline
olution  has  been  suggested  as  an  alternative  in  some  cir-
umstances.  It  is  a  safe,  non-invasive  and  reproducible
rocedure  to  collect  cells  and  soluble  mediators  from  the
irways.7 During  the  past  decade  IS  has  been  recognized
s  a  very  useful  sampling  method  for  both  research  and
linical  use,  adding  valuable  information  for  the  diagnosis,
onitoring  and  treatment  response  prediction,  particularly
n  chronic  obstructive  lung  diseases  such  as  asthma  or
OPD.8--11 There  have  been  a  few  descriptions  about  IS  use
n  the  diagnosis  and  monitoring  of  ILDs.3,5,12,13 However,
ts  safety  and  usefulness  in  this  context  remains  uncertain
nd  controversial,  especially  its  potential  in  sampling  the
mmunological  and  inﬂammatory  events  in  the  deep  lung.
In  this  study,  our  main  aim  was  to  investigate  the  safety
nd  feasibility  of  the  IS  procedure  and  to  describe  sputum
nalysis,  when  compared  with  expected  reference  values,
n  patients  with  ILD.  In  a  selected  group  with  lymphocytic
lveolitis,  we  also  compared  the  IS  cellular  characteristics
ith  those  obtained  in  BALF  samples.
aterials and methods
ubjectswenty  consecutive  patients  attending  the  ILD  hospital
utpatient  clinic  underwent  sputum  induction.  The  proce-
ure  was  explained  to  the  patients  who  were  encouraged
o  cough  up  any  sputum  after  inhalation  of  4.5%  saline
55
Figure  1  Induced  sputum  smear  showing  numerous  polymor-
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iInduced  sputum  in  interstitial  lung  diseases  --  A  pilot  study  
solution  for  5  min.  If  no  sputum  was  obtained  and  lung
function  was  greater  than  80%  of  the  baseline,  the  test  con-
tinued  until  a  predeﬁned  maximum  induction  time  of  45  min.
Bronchoscopy  and  BALF  processing  was  performed  within  2
weeks  from  induced  sputum  examination,  as  part  of  rou-
tine  clinical  management,  according  to  the  recommended
guidelines  and  previous  reports.14,15 The  ﬁnal  diagnosis  was
established  by  a  respiratory  physician,  based  on  the  BALF
results  and  the  clinical,  radiological,  functional  and  patho-
logical  data.  Informed  written  consent  was  obtained  and  the
study  approved  by  the  Faculty  of  Medicine  of  Porto  ethical
committee.
Sputum  induction  and  processing
Sputum  induction  was  performed  using  an  inhalation  of
4.5%  saline  through  a  mouthpiece  connected  to  an  ultra-
sonic  nebulizer  OMRON  NE-U17  (Omron  Healthcare  Europe,
Netherlands)  on  the  maximum  output  settings.  Sputum
induction  and  processing  were  performed  according  to  the
ERS  task  force  recommendations16,17 using  hypertonic  saline
for  periods  of  5  min.  Baseline  and  post  200  g  of  salbu-
tamol  Peak  Expiratory  Flow  (PEF)  were  registered  using
Mini-Wright  Peak-Flow  Meter  (Clement-Clarke  International,
Harlow,  Essex,  UK).  The  induction  stopped  either  when  the
patient  produced  an  adequate  sample  of  sputum  or  45  min
of  inhalation  were  completed  or  if  PEF  dropped  below  80%
of  the  baseline  value.  After  induction,  all  sputum  macro-
scopically  free  of  salivary  contamination  was  selected  and
treated  with  dithiothreitol  (DTT,  SputolysinTM 10%  concen-
tration;  Calbiochem  Corporation,  San  Diego,  CA,  USA)  in
phosphate-buffered  saline.  The  suspension  was  centrifuged
and  the  cell  pellet  resuspended  and  stained  with  Trypan-
blue  for  viability  and  total  cell  numbers  per  milligram
of  processed  sputum.  Coded  cytospins  were  prepared  and
stained  using  May--Grünwald  Giemsa  for  differential  cell
counts  of  intact  bronchial  epithelial  cells  and  leukocyte,
up  to  a  total  of  500  nonsquamous  cells.  Sputum  samples
were  considered  adequate  if  they  contained  <80%  squamous
epithelial  cell  from  saliva.
Bronchoalveolar  lavage  ﬂuid  processing
BAL  was  performed  using  a  ﬁbrotic  bronchoscope  at  the  time
of  diagnosis,  according  to  ERS  guidelines.15 In  brief,  200  ml
sterile  saline  was  instilled  into  the  middle  lobe  subsegment
in  50  ml  aliquots.  Each  aliquot  was  immediately  and  gently
aspirated  with  a  syringe.  BALF  total  volume  was  measured
and  ﬁltered  through  sterile  double  layer  surgical  gauze  to
remove  mucus  and  pooled.  The  ﬁrst  aliquot  was  excluded.
A  Neubauer  Cell  Chamber  was  used  for  BALF  total  cell  count
and  differential  cell  count  on  cytospin  slides  stained  with
May--Grünwald-Giemsa.
Statistical  analysisData  are  expressed  as  medians  (P25--75).  Since  variables
were  not  normally  distributed,  the  nonparametric  Wilcoxon
test  was  used  to  compare  the  differences  in  differential  cell
counts  and  cell  subsets.  Correlations  between  different  cells
<
<
shonuclear  neutrophils  (May--Grünwald  Giemsa  stain,  original
agniﬁcation  400×).
rom  different  samples  (induced  sputum  and  BALF)  were
xamined  by  Spearman’s  rank  correlation  coefﬁcient.  A  p
alue  of  <0.05  was  considered  as  statistically  signiﬁcant.
esults
rom  the  20  subjects  (mean  age  49.4  ±  16.4  years,  70%
ale)  with  ILD,  7  had  sarcoidosis  (35%),  8 (40%)  hyper-
ensitivity  pneumonitis  (HP),  and  one  each  (5%)  idiopathic
ulmonary  ﬁbrosis,  Cryptogenic  Organizing  Pneumonia,
espiratory  Bronchiolitis  associated  with  Interstitial  Lung
iseases,  Churg-Strauss  syndrome  and  Silicosis.
A  sputum  sample  satisfactory  for  processing  was
btained  in  15  subjects  (75%),  with  an  induction  time
f  26.0  (21.0--33.5)  min,  and  a  variation  in  PEF  after
putum  induction  of  −5.9%  (−8.9  to  0.0).  In  one  sample,
ell  count  was  impossible  due  to  morphological  damage.
hree  patients  produced  an  inadequate  sputum  sample  for
rocessing  (2  with  sarcoidosis,  1  HP)  and  1  patient  with
arcoidosis  was  unable  to  produce  any  sputum  after  45  min
nduction.  The  induction  was  stopped  in  one  subject,  due
o  a  48%  PEF  fall  after  5  min  of  sputum  induction.
The  sputum  analysis  of  the  satisfactory  samples  showed
 cellular  viability  of  55.0%  (50.0--63.0),  with  a  total  cell
ount  of  5.2  (2.6--12.5)  ×  105/ml,  and  a  predominance  of
eutrophils  (Fig.  1).  Total  and  differential  cell  counts  in  IS
nd  BALF  are  shown  in  Table  1.  Except  for  eosinophils,  all
ell  counts  were  signiﬁcantly  different  in  the  two  samples
p  <  0.05).  When  compared  to  IS  reference  values18 our  sam-
les  showed  similar  number  of  total  cells  counts  (median  of
.8  ×  106 cells/g  vs  2.4  ×  106 cells/g)  and  neutrophil  counts
mean  47.4%,  expected  36.7%),  and  an  increased  percentage
f  lymphocytes  (mean  3.2%,  expected  0.5%)  and  eosinophils
mean  1.4%,  expected  0.0%).  Similarly,  BALF  samples  in  our
tudy  group  compared  to  expected  values19 had  an  increase
n  lymphocytes  (33.7  vs  <15.0%)  and  eosinophils  (3.8  vs
0.5%)  but  also  a  higher  percentage  of  neutrophils  (6.9  vs
3.0%).
No  signiﬁcant  correlations  were  found  between  induced
putum  and  BALF  total  and  differential  cell  counts  in  our
56  
Table  1  Total  (TCC)  and  differential  cell  count  in  induced
sputum  (IS)  and  paired  bronchoalveolar  lavage  ﬂuid  (BALF)
in the  15  cases  with  a  satisfactory  IS  sample.  Data  expressed
as median  (P25--75)  values.  Except  for  eosinophils,  all  cell
counts  were  signiﬁcantly  different  in  the  two  samples.
Induced  sputum Bronchoalveolar
lavage  ﬂuid
TCC  x  105/ml  5.2  (2.6--12.5)*  2.2  (1.4--2.6)**
Macrophages  (%)  13.4  (8.3--21.2)*  54.2  (41.6--61.2)**
Neutrophils  (%) 47.4  (13.3--65.4)*  4.0  (2.2--12.2)**
Lymphocytes  (%) 3.2 (1.9--4.5)* 32.8 (22.8--42.2)**
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*,** Wilcoxon test, p < 0.05.
tudy  group,  except  for  the  percentage  of  neutrophils  in
ipersensitivity  Pneumonitis  (rs =  0.9;  p  =  0.05).
Table  2  presents  the  sputum  analysis  in  the  two  patient’s
ubgroups  with  a  lymphocytic  alveolitis:  sarcoidosis  and
ypersensitivity  pneumonitis.  Both  pathologies  showed  sim-
lar  total  cell  counts  (9.6  vs  10.8  × 105/ml),  and  increased
ymphocyte  numbers  (4.4  vs  3.9%).  However,  signiﬁcantly
igher  neutrophil  counts  were  found  in  HP  samples  (65.4%  vs
0.6%,  p  <  0.05).  A  similar  pattern  was  seen  in  BALF  samples
9.2%  vs  2.8%  p  <  0.05).
iscussion
n  this  study  we  aimed  to  assess  the  safety  and  feasibility  of
nduced  sputum  in  interstitial  lung  diseases  and  to  compare
he  IS  cellular  ﬁndings  with  those  of  BALF  in  newly  diag-
osed  patients.  We  obtained  a  satisfactory  sputum  result
ith  differential  cell  counts  in  15  of  the  20  subjects,  and  the
rocedure  was  well  tolerated  (only  one  patient  experienced
 signiﬁcant  PEF  fall  during  the  induction).
Although  total  and  differential  cell  counts  in  the  paired
S  and  BALF  samples  were  different,  conﬁrming  that
hese  methods  predominantly  sample  diverse  anatomical
ompartments  (respectively,  the  airways  and  the  deep
o
e
p
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Table  2  Comparison  of  total  (TCC)  and  differential  cell  counts  in
(n =  5)  and  hypersensitivity  pneumonitis  (n  =  5).  Data  expressed  as  
Sarcoidosis  
Age,  years  56.0  (50.0--59.0
Gender (F/M)  2/3  
Smoking status
Current  2  
Never 1  
Former 2  
Induced sputum
TCC  ×  105/ml  9.6  (2.7--12.5)  
Macrophages  (%)  15.2  (12.1--32.4
Neutrophils  (%)  10.6  (7.5--37.9)*
Lymphocytes  (%)  4.4  (2.4--4.5)  
Eosinophils  (%)  1.4  (0.3--3.9)  
* p < 0.05, Mann--Whitney.L.  Araújo  et  al.
ung),  the  results  of  this  pilot  study  showed  that,  compared
o  expected  reference  values,  there  was  an  increased  num-
er  of  lymphocytes  and  eosinophils  in  both  samples.18,19 In
he  subgroup  of  patients  with  hypersensitivity  pneumonitis
he  relative  numbers  of  neutrophils  in  induced  sputum  sig-
iﬁcantly  correlated  with  BALF  counts.  Moreover,  in  these
atients  neutrophils  were  signiﬁcantly  increased  in  both  IS
nd  BALF  when  compared  to  sarcoidosis  (Table  2),  another
LD  typically  occurring  with  a  lymphocytic  alveolitis.
Although  bronchial  hyperreactivity  has  been  recognized
n  patients  with  ILD20 and  hypertonic  saline  inhalation  can
nduce  bronchoconstriction  and  cough,21 sputum  induction
howed  itself  to  be  safe  in  our  series,  as  it  has  in  previous
eports.3,5 Only  one  patient  experienced  a  signiﬁcant  bron-
hoconstriction  during  the  induction  (a  63  years  old  man,
ith  a  suspected  HP,  pulmonary  emphysema  and  a  slight
ncrease  in  BAL  eosinophils  of  1.2%).
We  obtained  a  satisfactory  sputum  sample  in  15  subjects
75%).  Sobiecka  and  co-workers3 reported  an  overall  suc-
ess  rate  of  56%  (33/59  patients  with  ILD)  although  with
iffering  success  rates  between  diseases  (7/7  in  patients
ith  idiopathic  pulmonary  ﬁbrosis,  11/16  in  hypersensitivity
neumonitis  and  15/36  in  sarcoidosis).  These  results  con-
rast  with  data  from  D’Ippolito  et  al.  that  reported  a  100%
uccess  rate  both  in  sarcoidosis12 and  hypersensitivity  pneu-
onitis  patients.13 However,  to  the  best  of  our  knowledge,
o  speciﬁc  study  evaluating  the  feasibility,  safety  and  func-
ional  effects  of  IS  in  ILD  has  been  published.6 The  sputum
nalysis  of  the  satisfactory  samples  we  obtained  showed
 slightly  lower  cellular  viability  than  that  expected  for
ealthy  subjects  (55%  vs  72%),  but  still  within  an  acceptable
ange.22
Apart  from  eosinophils  counts,  total  and  differential  cell
ounts  in  the  paired  BALF  and  IS  samples  were  different,
uggesting  that  diverse  lung  compartments  are  sampled.  A
tudy  by  Fireman23 reporting  segmental  lavages  at  differ-
nt  depths  within  the  airways,  showed  that  the  proportion
f  neutrophils  decreased  from  central  (20--30%)  to  periph-
ral  (<2%)  airways,  with  a  corresponding  increase  in  the
roportion  of  macrophages,  which  suggests  that  IS  derives
rom  larger  airways  (rich  in  neutrophils)  and  BALF  samples
 induced  sputum  in  the  subgroup  of  patients  with  sarcoidosis
median  (P25--75)  values.
Hypersensitivity  pneumonitis
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from  more  distal  airways  and  alveolar  spaces.  In  support
of  this  hypothesis,  we  found  a  signiﬁcantly  higher  percent-
age  of  neutrophils  and  a  lower  percentage  of  macrophages
in  IS  compared  to  BALF,  as  reported  in  other  published
series.3,5,12,14,15
As  in  D’Ippolito  et  al.  studies12,13 no  signiﬁcant  corre-
lation  was  found  between  the  percentage  of  lymphocytes
recovered  by  both  techniques  in  this  study.  However,  com-
pared  to  IS  reference  values,18 our  series  showed  similar
total  cell  counts  but  with  a  higher  lymphocyte  relative
count.  Immunophenotyping  of  lymphocyte  subsets  in  IS  has
been  suggested  as  a  complementary  method  for  the  diag-
nosis  and  monitoring  of  patients  with  lymphocytic  lung
inﬂammation,  such  as  sarcoidosis.  In  fact,  Fireman  et  al.
reported  that  a  CD4/CD8  >  2.5  in  IS  had  a  positive  predicted
value  of  82%  in  distinguishing  sarcoidosis  from  other  non-
granulomatous  ILD.  Moodley  et  al.14 and  Sobiecka  et  al.3
also  found  in  sarcoidosis  a  signiﬁcant  correlation  between
IS  and  BALF  CD4+/CD8+,  in  spite  of  no  correlations  in  the
differential  cell  counts  of  the  two  samples.  In  our  series,  we
also  performed  ﬂow-cytometry  analysis  of  IS  lymphocytes
in  a  limited  number  of  sarcoidosis  cases,  and  we  found  a
CD4+/CD8+  >  2.5  in  3  of  the  4  tested  cases  (data  not  shown).
An  interesting  observation  in  our  small  series  was
that,  compared  to  sarcoidosis,  hypersensitivity  pneumoni-
tis  patients  had  signiﬁcantly  higher  neutrophil  count,  both
in  IS  and  BALF,  which  correlated  signiﬁcantly  in  both  sam-
ples.  This  possibly  reﬂects  the  pathological  features  of
hypersensitivity  pneumonitis,  where  increased  numbers  of
neutrophils  have  been  found,  especially  in  recurrent  symp-
tomatic  forms.24 However,  the  ﬁve  patients  included  had
heterogeneous  presentations  and  outcomes,  making  it  difﬁ-
cult  to  establish  any  association  between  the  high  neutrophil
counts  and  the  disease  phenotype.  One  patient  had  an  acute
presentation,  two  subacute  and  two  other  chronic  presenta-
tions.  There  was  only  one  patient  with  a  ﬁbrous  pattern  on
High  Resolution  Computed  Axial  Tomography  scan  while  the
other  four  had  mosaic  and/or  ground  glass  pattern.  In  terms
of  clinical  evolution,  three  patients  had  disease  regression
after  exposure  cessation  and  corticotherapy,  one  in  a  sta-
ble  chronic  form  and  another  had  progressive  deterioration,
dying  within  two  years  of  the  diagnosis.
Our  pilot  study  has  some  limitations  for  the  general-
ization  of  results.  Firstly,  the  studied  sample  is  small  and
heterogeneous,  making  it  difﬁcult  to  assess  the  role  of  IS  in
different  ILD  and  so  further  studies,  comparing  the  inﬂam-
matory  proﬁles  found  in  IS  and  BALF,  are  needed.  However,
this  population  did  enable  us  to  evaluate  the  feasibility  and
safety  of  IS  in  ILD.  Secondly,  although  we  have  shown  that  IS
in  ILD  is  feasible  and  well  tolerated,  the  procedure  is  time-
consuming  to  perform  and  process  and  it  needs  signiﬁcant
technical  support,  limiting  its  use  to  specialized  centers.10
The  integration  of  bronchoalveolar  lavage  results  with
clinical,  radiological,  functional  and  pathological  data
remains  the  gold-standard  approach  for  the  evaluation  of
interstitial  lung  diseases.  Although  BALF  is  a  minimally
invasive  technique,  with  minimal  risk  under  the  current
guidelines,  it  cannot  be  performed  in  all  patients  and  is
costly  and  questionable  in  terms  of  follow-up.  We  have
shown  that  induced  sputum  is  feasible  and  safe  in  this
group  of  patients.  Being  a  less  expensive,  less  invasive
and  repeatable  method,  induced  sputum  is  an  interesting
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esearch  and  clinical  tool  in  the  management  of  interstitial
ung  diseases.22,25 Further  studies  are  needed  to  establish
he  promising  role  of  induced  sputum  in  the  diagnosis  and
ollow-up  of  interstitial  lung  diseases.
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